MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.01
+0.28
+2.88%
Closed 16:00 01/29 EST
OPEN
9.75
PREV CLOSE
9.73
HIGH
10.18
LOW
9.75
VOLUME
87.75K
TURNOVER
--
52 WEEK HIGH
10.88
52 WEEK LOW
4.140
MARKET CAP
992.35M
P/E (TTM)
-13.1193
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MESO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MESO News

  • The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
  • Benzinga.5d ago
  • Is Mesoblast Limited's (ASX:MSB) CEO Being Overpaid?
  • Simply Wall St..6d ago
  • Will Mesoblast Continue to Surge Higher?
  • Zacks.6d ago
  • Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast
  • Zacks.01/20 14:59

More

Industry

Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About MESO

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
More

Webull offers Mesoblast limited (ADR) (MESO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.